Global RNA Interference (RNAi) Drug Delivery Market Growth 2023-2029

Global RNA Interference (RNAi) Drug Delivery Market Growth 2023-2029

LPI (LP Information)' newest research report, the “RNA Interference (RNAi) Drug Delivery Industry Forecast” looks at past sales and reviews total world RNA Interference (RNAi) Drug Delivery sales in 2022, providing a comprehensive analysis by region and market sector of projected RNA Interference (RNAi) Drug Delivery sales for 2023 through 2029. With RNA Interference (RNAi) Drug Delivery sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Interference (RNAi) Drug Delivery industry.

This Insight Report provides a comprehensive analysis of the global RNA Interference (RNAi) Drug Delivery landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Interference (RNAi) Drug Delivery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global RNA Interference (RNAi) Drug Delivery market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Interference (RNAi) Drug Delivery and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Interference (RNAi) Drug Delivery.

The global RNA Interference (RNAi) Drug Delivery market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for RNA Interference (RNAi) Drug Delivery is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for RNA Interference (RNAi) Drug Delivery is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for RNA Interference (RNAi) Drug Delivery is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key RNA Interference (RNAi) Drug Delivery players cover Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp and Quark Pharmaceuticals Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of RNA Interference (RNAi) Drug Delivery market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology

Segmentation by application
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc

Key Questions Addressed in this Report

What is the 10-year outlook for the global RNA Interference (RNAi) Drug Delivery market?

What factors are driving RNA Interference (RNAi) Drug Delivery market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do RNA Interference (RNAi) Drug Delivery market opportunities vary by end market size?

How does RNA Interference (RNAi) Drug Delivery break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.